“I may not stand at the bedside, but the systems I build and the standards I uphold help ensure that patients around the world receive therapies they can trust. That is the responsibility, and the legacy, I carry every day.”
– Sharis Hazel
There is a kind of leadership that rarely makes headlines but quietly holds the most consequential systems in the world together. It does not emerge on the front lines of patient care, yet its absence would be felt in every hospital, every clinic, and every pharmacy on earth. It is the leadership of those who build the quality frameworks, regulatory standards, and operational cultures that determine whether life-saving therapies reach patients safely and reliably. Sharis Hazel has spent more than two decades at precisely that intersection, and her career is a study in what principled, purpose-driven leadership looks like when it is sustained across the full arc of a professional life.
As Senior Vice President of Quality, Regulatory Affairs, and Operational Excellence at Proesis Biologics, Sharis carries enterprise-wide responsibility for the systems that protect product integrity and, by extension, patient safety. Her mandate spans inspection readiness, risk-based quality management, digital transformation, regulatory compliance, and the cultivation of organizational cultures where doing the right thing is not aspirational it is simply how work gets done. The scope of that responsibility is vast. The clarity of purpose behind it has never wavered.
A CALLING REDIRECTED: FROM MEDICINE TO THE SYSTEMS THAT MAKE MEDICINE SAFE
Sharis Hazel’s path into the biopharmaceutical industry did not begin with a master plan. It began with a calling. Early in her life, she aspired to enter medicine directly, drawn by the desire to make a tangible difference in people’s health outcomes. When life redirected that path, it led her somewhere she had not anticipated but would come to understand as deeply aligned with her original purpose. Bioscience, and specifically quality assurance within it, offered something that few professional disciplines can claim: the opportunity to protect patients at scale.
The realization came early and shaped everything that followed. Although she would never stand at a bedside, the systems she built and the standards she upheld would determine whether the therapies delivered to patients were safe, effective, and worthy of trust. That understanding transformed quality assurance from a function into a vocation. “I began in quality assurance, where I quickly learned that quality is not simply a function,” she reflects. “It is an organizational mindset.”
That conviction that quality is a culture to be built rather than a checklist to be managed became the philosophical foundation from which every subsequent milestone in her career would grow. It is the lens through which she evaluates organizations, designs systems, and develops the leaders who will carry these responsibilities forward.
TWO DECADES OF LESSONS: TRANSPARENCY, ACCOUNTABILITY, AND THE HUMAN SIDE OF COMPLIANCE
Over more than twenty years in pharmaceutical and biologics environments, Sharis has led organizations through some of the most demanding situations that regulated industries produce: regulatory inspections, remediation efforts, and large-scale transformation programs. Each of those experiences added a layer of understanding that purely academic training cannot replicate. Inspections test not just the quality of documentation but the cohesion of organizational culture. Remediation demands honest reckoning with failure and the discipline to rebuild better. Transformation requires leaders who can hold the tension between urgency and rigor without sacrificing either.
What those experiences reinforced, again and again, was that sustainable success in this field is built on three interdependent foundations: transparency, accountability, and consistency. Technical expertise is necessary but not sufficient. The leader who can read a regulatory framework with precision but cannot cultivate trust within a team will eventually find that the quality culture they are trying to build has no roots.
Sharis learned this not by reading about it but by living through it. The leaders who left the deepest impressions on her were those who empowered their teams rather than merely directing them, who created environments where raising a concern was seen as strength rather than disruption, and who held themselves to the same standards of accountability they expected of others. Those lessons are now embedded in her own leadership model.
“Inspection readiness must be a continuous state rather than a periodic effort. When readiness is embedded into daily operations, organizations are always prepared.”
ENTERPRISE QUALITY AT PROESIS BIOLOGICS: PROTECTING PATIENTS THROUGH SYSTEMS THAT SCALE
At Proesis Biologics, Sharis’s priorities as Senior Vice President reflect both the complexity of the role and the clarity of its ultimate purpose. Strengthening enterprise quality systems, embedding risk-based decision-making across the organization, and maintaining continuous inspection readiness are not separate workstreams. They are interconnected elements of a single strategic posture: being genuinely ready, at all times, to demonstrate that every process, every batch, every decision was made in service of patient safety.
Her approach to inspection readiness is instructive. Many organizations treat inspections as events to prepare for intensive periods of review and remediation that precede an expected regulatory visit. Sharis treats it as a continuous state. Strong governance, routine internal audits, real-time metrics, and a culture of accountability are not activated when an inspection is imminent. They are simply how the organization operates. When readiness is embedded into daily work rather than layered on top of it, the distinction between inspection mode and normal mode disappears.
That philosophy extends to her approach to quality culture more broadly. A strong quality culture, in her view, is defined by employees who understand their personal role in protecting patients and who take genuine ownership of quality outcomes rather than treating compliance as someone else’s responsibility. Building that culture is a leadership challenge as much as a technical one, and it requires consistent reinforcement from the top of the organization down to the operational floor.
THE EVOLVING ROLE OF QUALITY LEADERSHIP: FROM COMPLIANCE FUNCTION TO STRATEGIC PARTNER
The biopharma industry is changing faster than at perhaps any point in its history. Advanced therapies are redefining what is biologically possible. Digital transformation is reshaping how data is generated, managed, and interpreted. Regulatory frameworks are evolving in response, and the pace of change shows no sign of slowing. In that environment, the role of quality leadership has undergone a fundamental transformation.
Where quality functions were once positioned primarily as compliance overseers the last line of defense before a product reached the market they are increasingly expected to serve as strategic partners in the innovation process itself. That shift demands a different kind of quality leader: one who understands not just what the regulations require but why they exist, and who can engage productively with research, development, manufacturing, and commercial teams to ensure that innovation is pursued with appropriate rigor rather than in spite of it.
Sharis navigates this evolution with a clear framework: speed and agility in innovation must be balanced with regulatory rigor, and neither can be sacrificed for the other. That balance is not always easy to maintain, particularly when competitive pressures or organizational enthusiasm for a new therapy creates urgency to move faster than quality systems can responsibly support. Her role is to hold that line with both firmness and strategic credibility to be the voice that says the organization can move quickly and safely, but not by cutting corners that exist to protect patients.
DATA, DIGITAL TOOLS, AND THE FUTURE OF QUALITY MANAGEMENT
Among the most significant shifts Sharis has witnessed and guided over her career is the integration of data analytics and digital tools into quality management processes. The transition from reactive to proactive quality management from responding to problems after they occur to identifying risks before they materialize is now both possible and expected, driven by the sophistication of predictive analytics and trending tools available to quality professionals today.
The organizations performing best in this environment are those that have built quality systems capable of generating real-time insight rather than periodic summaries. Electronic Quality Management Systems, automated compliance tracking, and predictive risk modeling are not futuristic aspirations. They are becoming operational realities that distinguish high-performing organizations from those still working with fragmented systems and inconsistent documentation practices.
Digital transformation, however, is not without its own risks in a regulated environment. Rapid adoption of new technologies can outpace the maturity of the quality systems designed to govern them, creating gaps that regulators will inevitably find. Sharis is attentive to that tension. Technology enhances traceability and efficiency, but human oversight remains essential. The organizations that benefit most from digital tools are those that integrate them with clear governance from the beginning rather than retrofitting controls after implementation.
LEAN SIX SIGMA IN PRACTICE: WHERE METHODOLOGY MEETS MEANINGFUL CHANGE
Sharis’s credentials in Lean Six Sigma and her ASQ certifications are not credentials she acquired for their titles. They represent a structured approach to problem-solving that has produced measurable results across multiple operational contexts throughout her career. In deviation management, applying Lean methodologies to streamline workflows, standardize investigative processes, and eliminate redundancies accelerated closure timelines while simultaneously strengthening compliance and accountability outcomes that are often assumed to be in tension with each other.
In plasma donation center operations, she led targeted continuous improvement initiatives that redesigned training timelines, eliminated redundant processes, and improved workforce readiness in ways that had direct impact on the donor floor. By standardizing onboarding and streamlining competency development, the organization was able to accelerate the readiness of its workforce without compromising quality or compliance standards. The results were not marginal adjustments. The elimination of approximately 80 percent of paper-based processes enhanced data accuracy, improved traceability, and delivered efficiency gains that scaled across operations.
She is currently pursuing a Master of Science in Quality Systems and Improvement Management, with completion expected in December 2026. This pursuit reflects her continued commitment to advancing her systems thinking capabilities while further reinforcing her industry certifications
“This work is bigger than compliance, certifications, or career advancement. At its core, quality leadership is about stewardship of systems, standards, and, most importantly, patient trust.”
REPRESENTATION AS RESPONSIBILITY: INCLUSIVE LEADERSHIP AND THE NEXT GENERATION
Among the convictions that Sharis carries most personally is the belief that diversity and inclusive leadership are not peripheral concerns in high-performance organizations but central to their capacity for innovation, resilience, and long-term success. Different perspectives produce better problem-solving. Inclusive governance structures build teams capable of navigating complexity that homogeneous groups often cannot see clearly enough to address.
But for Sharis, the dimension of representation carries a meaning that goes beyond organizational performance metrics. As a Black woman who has reached senior leadership in a field where such representation remains uncommon, she understands that her visibility carries weight for those who are watching. Young Black women navigating their own professional journeys in science, quality, and regulatory affairs need to see something familiar in the people who occupy leadership positions. That visibility does not just inspire aspiration. It validates possibility in a way that no amount of encouragement from the sidelines can replicate.
“Representation not only inspires aspiration, but it also validates possibility,” she says. “It is important that they see something familiar in me and recognize that leadership at this level is not out of reach.” That sense of responsibility to create pathways, remove barriers, and ensure that the next generation of leaders sees themselves reflected in the spaces where decisions are made informs how she mentors, how she builds teams, and how she thinks about the broader obligations that come with occupying a position of influence.
ADVICE FOR THE NEXT GENERATION: LEAD WITH INTEGRITY, BUILD FOR MEANING
When Sharis speaks to those aspiring to build careers in quality leadership and regulatory affairs, she does not begin with certifications or technical competencies. She begins with purpose. The work, she tells them, is bigger than any credential or career milestone. It is stewardship of systems, of standards, and above all of the trust that patients place in the therapies that reach them.
Build expertise, she counsels. Remain genuinely curious in a field where the science, the technology, and the regulatory landscape are always evolving. Pursue excellence without apology. But never allow the pursuit of professional achievement to obscure the human stakes of the work. The quality professional who understands that every deviation closed, every audit completed, and every inspection passed represents a patient protected somewhere in the world will approach the work differently than one who sees it primarily as a compliance function to be managed.
“If you lead with integrity and purpose,” she reflects, “your career will not only be successful but also meaningful. And ultimately, that is what defines a lasting legacy.” It is a summation that mirrors her own trajectory with remarkable fidelity a career built not by chasing advancement but by committing, consistently and deeply, to the responsibility of the work itself.
A LEGACY WRITTEN IN THE SAFETY OF PATIENTS
Sharis Hazel represents the kind of leadership that the biopharmaceutical industry needs most in a period of rapid change: grounded in deep technical expertise, shaped by two decades of hard-won operational experience, animated by an unwavering commitment to patient safety, and guided by the conviction that how an organization builds its quality culture is inseparable from what kind of organization it ultimately becomes.
She does not hold her position at the highest levels of quality and regulatory leadership because the systems she oversees passed an inspection. She holds it because the cultures she has built, the teams she has developed, and the standards she has championed have made organizations genuinely better not just more compliant. That is the difference between leadership that satisfies a regulator and leadership that protects a patient. Sharis Hazel has always understood which one matters more.
